| Nasvac vaccine: Therapeutic recombinant vaccine |
Chronic hepatitis B virus infection |
Viral diseases |
|
| Heberprot-P: Recombinant human epidermal growth factor, for scarring |
Diabetic foot ulcer |
Diabetes and scarring |
|
| CIGB 300: Proapoptotic peptide that acts on phosphorylation mediated by CK2 |
Cervical Cancer |
Oncology |
|
| CIGB 845: Neuroprotective agent |
Neuroprotection |
Neurology |
|
| Nasalferon: Nasal pharmaceutical solution, containing recombinant human interferon alpha 2b |
Prophylaxis of SARS-CoV-2 virus infection |
Viral diseases |
|
| Heberprovac: Prostate Cancer Vaccine |
Prostate cancer |
Oncology |
|
| Heberferon: Pharmaceutical formulation for parenteral use containing IFN alpha2b and gamma. Antiviral action. |
COVID-19 |
Viral diseases |
|
| Heberferon: Pharmaceutical formulation for parenteral use containing IFN alfa2b and gamma. Anti-tumor action |
Basal cell carcinoma |
Oncology |
|
| CIGB 814: Deadly type of modified peptic ligament |
Rheumatoid arthritis |
Autoimmune diseases |
|
| CIGB 500: Cytoprotective agent of cardiac tissue |
Reduce the extent of myocardial infarction and protect the epithelial organs of the body from damage caused by ischemia-reperfusion events |
Cardiology |
|
| CIGB 247: Active Immunotherapy for Cancer Treatment |
Hepatocarcinoma |
Oncología |
|
| CIGB 247: Active Immunotherapy for Cancer Treatment |
Ovarian cancer |
Oncology |
|
| CR3 AIDS vaccine |
Aids |
Viral diseases |
|
| CIGB 552: Anti-tumor peptide targeting molecular targets |
Cancer |
Oncology |
|
| CIGB 470: Active Immunotherapy for Age-Related Macular Degeneration. |
Age-related macular degeneration (AMD) |
Oftalmology |
|
| CIGB 325: Proapoptotic peptide that acts on phosphorylation mediated by CK2 |
COVID-19 |
Viral diseases |
|
| CIGB 300: Proapoptotic peptide that acts on phosphorylation mediated by CK2 |
Lung cancer |
Oncology |
|
| CIGB 300: Proapoptotic peptide that acts on phosphorylation mediated by CK2 |
Leukemia |
Oncology |
|
| CIGB 2020: Therapy for the activation of multiple receptors of the innate immune system |
Innate immune response |
Viral diseases |
|
| Tir 8: IL-1 inhibitor |
Cancer, rheumatoid arthritis |
Oncology, Autoimmune Diseases |
|
| Jusvinza (CIGB 258): Therapy for COVID-19 |
COVID-19 |
Viral diseases |
|
| IFN Beta-Ring FCB (EM) |
Multiple sclerosis |
Neurology |
|
| HCV Vaccine: Hepatitis C virus preventive vaccine |
Hepatitis C virus |
Viral diseases |
|
| FCB stroke ring |
Ictus |
Neurology |
|
| Dengue vaccine |
Dengue |
Viral diseases |
|
| CIGB 55: IL-15 Antagonist Peptide |
Rheumatoid arthritis |
Autoimmune diseases |
|
| CIGB 540: Antifibrotic peptide |
Keloids and hypertrophic scars |
Dermatology |
|
| CIGB 530: Hepatic cytoprotective agent |
Liver fibrosis |
gastroenterology |
|
| CIGB 50: IL-15 AR vaccine |
Rheumatoid arthritis |
autoimmune diseases |
|
| CIGB 428: Treatment for Diabetic Neuropathy |
Diabetic Neuropathy |
Neurology |
|
| CIGB 210: Therapy for COVID-19 |
COVID-19 |
Infectious diseases |
|
| CIGB 210: Anti-HIV therapy |
HIV |
Infectious diseases |
|
| CIGB 166: Anti-VEGF antibody |
Age-related macular degeneration (AMD) |
Oftalmology |
|
| Antivirals against dengue |
Dengue |
Viral diseases |
|
| Acellular Pertussis Vaccine |
Whooping cough |
Infectious diseases |
|
